These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10155266)

  • 1. The costs of treating febrile neutropenia in patients with malignant blood disorders.
    Leese B; Collin R; Clark DJ
    Pharmacoeconomics; 1994 Sep; 6(3):233-9. PubMed ID: 10155266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients.
    Dranitsaris G; Tran TM; McGeer A; Narine L
    Pharmacoeconomics; 1995 Jan; 7(1):49-62. PubMed ID: 10155293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
    Elting LS; Rubenstein EB; Rolston K; Cantor SB; Martin CG; Kurtin D; Rodriguez S; Lam T; Kanesan K; Bodey G
    J Clin Oncol; 2000 Nov; 18(21):3699-706. PubMed ID: 11054443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of treating febrile neutropenia in six U.K. Hospitals.
    Leese B
    Eur J Cancer; 1993; 29A Suppl 7():S15-8. PubMed ID: 7508725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.
    O'Brien C; Fogarty E; Walsh C; Dempsey O; Barry M; Kennedy MJ; McCullagh L
    Eur J Cancer Care (Engl); 2015; 24(1):125-32. PubMed ID: 24472035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
    Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.
    Hendricks AM; Loggers ET; Talcott JA
    J Clin Oncol; 2011 Oct; 29(30):3984-9. PubMed ID: 21931037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.
    Bucaneve G; Menichetti F; Del Favero A
    Pharmacoeconomics; 1999 Jan; 15(1):85-95. PubMed ID: 10345160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
    Goa KL; Bryson HM
    Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
    Bennett CL; Calhoun EA
    Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
    Cagnoni PJ; Walsh TJ; Prendergast MM; Bodensteiner D; Hiemenz S; Greenberg RN; Arndt CA; Schuster M; Seibel N; Yeldandi V; Tong KB
    J Clin Oncol; 2000 Jun; 18(12):2476-83. PubMed ID: 10856108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer.
    Castagnola E; Paola D; Giacchino R; Rossi R; Viscoli C
    Support Care Cancer; 1998 Nov; 6(6):524-8. PubMed ID: 9833301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S; Palmer S; Ellis-Pegler R
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
    Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
    Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.
    Mathew S; Adel N; Rice RD; Panageas K; Duck ET; Comenzo RL; Kewalramani T; Nimer SD
    Bone Marrow Transplant; 2010 Oct; 45(10):1522-7. PubMed ID: 20062102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
    Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
    Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.